Iressa gefitinib: Additional Phase III data
Additional data from the open-label, Asian Phase III IPASS trial in 1,217 treatment-naïve advanced NSCLC patients showed that Iressa produced a median OS of 18.8 months vs. 17.4 months for carboplatin/paclitaxel chemotherapy (p=0.11). Iressa also produced non-significant reductions in median OS in EGFR mutation-positive patients (n=261; 21.6 vs. 21.9 months) and in EGFR mutation-negative patients (n=176; 11.2 vs. 12.7 months) compared with chemotherapy. AstraZeneca said the trial was not powered to determine superiority of Iressa in the mutation-positive group. Iressa increased median OS in EGFR mutation-unknown patients compared with chemotherapy (n=780; 18.9 vs. 17.2 months). Data were presented at the European Society for Medical Oncology meeting in Milan. ...